Pfizer invests $43 billion to battle cancer

New york & bothell, wash.--(business wire)--pfizer inc. (nyse: pfe) and seagen inc. (nasdaq: sgen) today announced that they have entered into a definitive merger agreement under which pfizer will acquire seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per seagen share for a total enterprise value of $43 billion. the boards of directors of both companies have unanimously approved the transaction.
SGEN Ratings Summary
SGEN Quant Ranking